|
AIM | Aim Immunotech Inc. |
|
|
AIM | Aim Immunotech Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.33 |
| Leverage | 78.57% |
| Market Cap | $ 8.8m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -23.7m |
| Margin | -704.42% |
AIM ImmunoTech Inc., an immunpharmaceutical company, focuses on research and development of therapies to treat multiple types of cancers, viruses, and immunodeficiency disorders in the United States. The company is headquartered in Ocala, Florida.